SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2023
To assess the efficacy and safety of SH-1028 tablets versus placebo in stage II-IIIB non-small cell lung cancer (NSCLC) patients with sensitizing epidermal growth factor receptor (EGFR) mutations, following complete tumor resection, with or without adjuvant chemotherapy.
Epistemonikos ID: 6ceaa627bd5ed640b13afdd9e8c2b241f1956f5c
First added on: May 15, 2024